{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:26:39Z","timestamp":1790742399456,"version":"4.1.0"},"reference-count":94,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T00:00:00Z","timestamp":1545091200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T00:00:00Z","timestamp":1545091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>Portopulmonary hypertension (PoPH) is a form of pulmonary arterial hypertension (PAH) that can develop as a complication of portal hypertension. Treatment of PoPH includes PAH\u2010specific therapies, and in certain cases, such therapies are necessary to facilitate a successful liver transplantation. A significant number of barriers may limit the adequate treatment of patients with PoPH and explain the poorer survival of these patients when compared to patients with other types of PAH. Until recently, only one randomized controlled trial has included PoPH patients, and the majority of treatment data have been derived from relatively small observational studies. In the present article, we review some of the barriers in the treatment of patients with PoPH and implications for liver transplantation.<\/jats:p>","DOI":"10.1002\/hep.30197","type":"journal-article","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T12:14:07Z","timestamp":1533125647000},"page":"431-443","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":43,"title":["Treatment Barriers in Portopulmonary Hypertension"],"prefix":"10.1097","volume":"69","author":[{"given":"Batool","family":"AbuHalimeh","sequence":"first","affiliation":[{"name":"Pathobiology Division,Lerner Research Institute, Cleveland Clinic,OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Krowka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology and Department of Pulmonary and Critical Care Medicine,Mayo Clinic,Rochester,MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano R.","family":"Tonelli","sequence":"additional","affiliation":[{"name":"Department of Pulmonary, Allergy and Critical Care Medicine,Respiratory Institute, Cleveland Clinic,Cleveland,OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,12,18]]},"reference":[{"key":"hep30197-bib-0001-20250401","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/lt.500091215","article-title":"Portopulmonary hypertension: diagnostic advances and caveats","volume":"9","year":"2003","journal-title":"Liver Transpl"},{"key":"hep30197-bib-0002-20250401","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1183\/09031936.04.00010904","article-title":"Committee ETFP\u2010HVDPS. Pulmonary\u2010hepatic vascular disorders (PHD)","volume":"24","year":"2004","journal-title":"Eur Respir J"},{"key":"hep30197-bib-0003-20250401","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1016\/j.jacc.2004.02.037","article-title":"Clinical classification of pulmonary hypertension","volume":"43","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl. 1","key":"hep30197-bib-0004-20250401","first-page":"1","article-title":"The fifth world symposium on pulmonary hypertension","volume":"42","year":"2014","journal-title":"Turk Kardiyol Dern Ars"},{"key":"hep30197-bib-0005-20250401","first-page":"74","article-title":"Hepatic venous pressure gradient measurement: time to learn!","volume":"27","year":"2008","journal-title":"Indian J Gastroenterol"},{"key":"hep30197-bib-0006-20250401","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/0016-5085(91)90225-A","article-title":"Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics","volume":"100","year":"1991","journal-title":"Gastroenterology"},{"key":"hep30197-bib-0007-20250401","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/lt.20459","article-title":"Hemodynamics and survival of patients with portopulmonary hypertension","volume":"11","year":"2005","journal-title":"Liver Transpl"},{"key":"hep30197-bib-0008-20250401","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1053\/jhep.2003.50060","article-title":"Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study","volume":"37","year":"2003","journal-title":"Hepatology"},{"key":"hep30197-bib-0009-20250401","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/hep.21431","article-title":"Portopulmonary hypertension: results from a 10\u2010year screening algorithm","volume":"44","year":"2006","journal-title":"Hepatology"},{"key":"hep30197-bib-0010-20250401","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1378\/chest.11-0160","article-title":"Portopulmonary hypertension: a report from the US\u2010based REVEAL registry","volume":"141","year":"2012","journal-title":"Chest"},{"key":"hep30197-bib-0011-20250401","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.healun.2016.12.014","article-title":"Survival in portopulmonary hypertension: outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry","volume":"36","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"hep30197-bib-0012-20250401","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1111\/j.1600-6143.2008.02384.x","article-title":"Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups","volume":"8","year":"2008","journal-title":"Am J Transplant"},{"key":"hep30197-bib-0013-20250401","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.healun.2004.01.017","article-title":"Novel use of sildenafil in the treatment of portopulmonary hypertension","volume":"24","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"hep30197-bib-0014-20250401","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejim.2017.05.028","article-title":"Portopulmonary hypertension and hepatorenal syndrome. Two faces of the same coin","volume":"43","year":"2017","journal-title":"Eur J Intern Med"},{"key":"hep30197-bib-0015-20250401","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1164\/rccm.200804-613OC","article-title":"Portopulmonary hypertension: survival and prognostic factors","volume":"178","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"hep30197-bib-0016-20250401","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/lt.20016","article-title":"Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database","volume":"10","year":"2004","journal-title":"Liver Transpl"},{"key":"hep30197-bib-0017-20250401","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1097\/TP.0000000000001229","article-title":"International Liver Transplant Society practice guidelines: diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension","volume":"100","year":"2016","journal-title":"Transplantation"},{"issue":"Suppl. 3","key":"hep30197-bib-0018-20250401","first-page":"S128","article-title":"Model for End\u2010Stage Liver Disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula","volume":"12","year":"2006","journal-title":"Liver Transpl"},{"key":"hep30197-bib-0019-20250401","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.cgh.2013.02.014","article-title":"Model for End\u2010Stage Liver Disease\u2013based organ allocation: managing the exceptions to the rules","volume":"11","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep30197-bib-0020-20250401","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"key":"hep30197-bib-0021-20250401","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/MEG.0b013e3283337130","article-title":"Portopulmonary hypertension: short review","volume":"22","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"hep30197-bib-0022-20250401","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-0032-1301731","article-title":"Portopulmonary hypertension","volume":"33","year":"2012","journal-title":"Semin Respir Crit Care Med"},{"key":"hep30197-bib-0023-20250401","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/TP.0000000000001517","article-title":"Frequency and outcomes of patients with increased mean pulmonary artery pressure at the time of liver transplantation","volume":"101","year":"2017","journal-title":"Transplantation"},{"key":"hep30197-bib-0024-20250401","doi-asserted-by":"crossref","first-page":"543","DOI":"10.4065\/71.6.543","article-title":"Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients","volume":"71","year":"1996","journal-title":"Mayo Clin Proc"},{"key":"hep30197-bib-0025-20250401","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.dld.2006.12.014","article-title":"Cirrhotic cardiomyopathy","volume":"39","year":"2007","journal-title":"Dig Liver Dis"},{"key":"hep30197-bib-0026-20250401","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/0002-9149(85)90507-7","article-title":"Echocardiographic findings before and after liver transplantation","volume":"55","year":"1985","journal-title":"Am J Cardiol"},{"key":"hep30197-bib-0027-20250401","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacc.2016.05.043","article-title":"High\u2010output heart failure: a 15\u2010year experience","volume":"68","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"hep30197-bib-0028-20250401","first-page":"528783","article-title":"Effect of PAH specific therapy on pulmonary hemodynamics and six\u2010minute walk distance in portopulmonary hypertension: a systematic review and meta\u2010analysis","volume":"2014","year":"2014","journal-title":"Pulm Med"},{"key":"hep30197-bib-0029-20250401","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1164\/rccm.201209-1583CI","article-title":"Pulmonary vascular complications of liver disease","volume":"187","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"hep30197-bib-0030-20250401","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/j.1600-6143.2006.01701.x","article-title":"The impact of treatment of portopulmonary hypertension on survival following liver transplantation","volume":"7","year":"2007","journal-title":"Am J Transplant"},{"key":"hep30197-bib-0031-20250401","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)","volume":"37","year":"2016","journal-title":"Eur Heart J"},{"key":"hep30197-bib-0032-20250401","doi-asserted-by":"crossref","first-page":"1700740","DOI":"10.1183\/13993003.00740-2017","article-title":"Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model","volume":"50","year":"2017","journal-title":"Eur Respir J"},{"key":"hep30197-bib-0033-20250401","doi-asserted-by":"crossref","first-page":"1700889","DOI":"10.1183\/13993003.00889-2017","article-title":"Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension","volume":"50","year":"2017","journal-title":"Eur Respir J"},{"key":"hep30197-bib-0034-20250401","article-title":"A comprehensive risk stratification at early follow\u2010up determines prognosis in pulmonary arterial hypertension","year":"2017","journal-title":"Eur Heart J"},{"key":"hep30197-bib-0035-20250401","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.3748\/wjg.v13.i29.3996","article-title":"Six minute walk test to assess functional capacity in chronic liver disease patients","volume":"13","year":"2007","journal-title":"World J Gastroenterol"},{"key":"hep30197-bib-0036-20250401","doi-asserted-by":"crossref","first-page":"e68364","DOI":"10.1371\/journal.pone.0068364","article-title":"NT pro BNP plasma level and atrial volume are linked to the severity of liver cirrhosis","volume":"8","year":"2013","journal-title":"PLoS One"},{"key":"hep30197-bib-0037-20250401","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1172\/JCI106044","article-title":"Cardiac hemodynamics in alcoholic patients with chronic liver disease and a presystolic gallop","volume":"48","year":"1969","journal-title":"J Clin Invest"},{"issue":"Suppl. 3","key":"hep30197-bib-0038-20250401","first-page":"S323","article-title":"Hemodynamic evaluation before liver transplantation: insights into the portal hypertensive syndrome","volume":"41","year":"2007","journal-title":"J Clin Gastroenterol"},{"key":"hep30197-bib-0039-20250401","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1183\/09031936.00110006","article-title":"PDE\u20105 inhibitors lower portal and pulmonary pressure in portopulmonary hypertension","volume":"29","year":"2007","journal-title":"Eur Respir J"},{"key":"hep30197-bib-0040-20250401","first-page":"A7357","article-title":"Riociguat treament for porto\u2010pulmonary hypertension: a subgroup analysis from the Patent\u20101 study","volume":"193","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"hep30197-bib-0041-20250401","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1183\/09031936.05.00080804","article-title":"Bosentan therapy for portopulmonary hypertension","volume":"25","year":"2005","journal-title":"Eur Respir J"},{"key":"hep30197-bib-0042-20250401","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1378\/chest.10-0574","article-title":"Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension","volume":"139","year":"2011","journal-title":"Chest"},{"key":"hep30197-bib-0043-20250401","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1432-2277.2008.00830.x","article-title":"Initial experience using continuous intravenous treprostinil to manage pulmonary arterial hypertension in patients with end\u2010stage liver disease","volume":"22","year":"2009","journal-title":"Transpl Int"},{"key":"hep30197-bib-0044-20250401","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1023\/A:1024784327783","article-title":"Influence of hepatic encephalopathy on health\u2010related quality of life in patients with cirrhosis","volume":"48","year":"2003","journal-title":"Dig Dis Sci"},{"key":"hep30197-bib-0045-20250401","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1023\/A:1011610427843","article-title":"Quality of life in cirrhotics with minimal hepatic encephalopathy","volume":"16","year":"2001","journal-title":"Metab Brain Dis"},{"key":"hep30197-bib-0046-20250401","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1183\/09031936.00032407","article-title":"Experience with inhaled iloprost and bosentan in portopulmonary hypertension","volume":"30","year":"2007","journal-title":"Eur Respir J"},{"key":"hep30197-bib-0047-20250401","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/lt.21997","article-title":"Acute and long\u2010term effects of inhaled iloprost in portopulmonary hypertension","volume":"16","year":"2010","journal-title":"Liver Transpl"},{"key":"hep30197-bib-0048-20250401","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1183\/09031936.06.00030206","article-title":"Sildenafil treatment for portopulmonary hypertension","volume":"28","year":"2006","journal-title":"Eur Respir J"},{"key":"hep30197-bib-0049-20250401","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0735-1097(03)00463-7","article-title":"Beraprost therapy for pulmonary arterial hypertension","volume":"41","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"hep30197-bib-0050-20250401","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2165\/00003088-199121010-00004","article-title":"Clinical pharmacokinetics in patients with liver disease","volume":"21","year":"1991","journal-title":"Clin Pharmacokinet"},{"key":"hep30197-bib-0051-20250401","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2165\/00003088-199937050-00004","article-title":"Effects of liver disease on pharmacokinetics","volume":"37","year":"1999","journal-title":"An update. Clin Pharmacokinet"},{"key":"hep30197-bib-0052-20250401","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1183\/09031936.00117511","article-title":"Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension","volume":"41","year":"2013","journal-title":"Eur Respir J"},{"issue":"Suppl. 1","key":"hep30197-bib-0053-20250401","first-page":"S5","article-title":"Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63\u20132521)","volume":"6","year":"2016","journal-title":"Pulm Circ"},{"key":"hep30197-bib-0054-20250401","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/MEG.0b013e3282f2bbb5","article-title":"Initially obscure hepatotoxicity attributed to sildenafil","volume":"20","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"hep30197-bib-0055-20250401","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","year":"2002","journal-title":"N Engl J Med"},{"key":"hep30197-bib-0056-20250401","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1067\/mcp.2001.114667","article-title":"The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions","volume":"69","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"hep30197-bib-0057-20250401","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1378\/chest.08-1028","article-title":"Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities","volume":"135","year":"2009","journal-title":"Chest"},{"key":"hep30197-bib-0058-20250401","first-page":"343","article-title":"The cytoprotective effect of iloprost against carbon tetrachloride induced necrosis in rat liver","volume":"95","year":"1997","journal-title":"Res Commun Mol Pathol Pharmacol"},{"key":"hep30197-bib-0059-20250401","first-page":"64","article-title":"Paracetamol toxicity and its prevention by cytoprotection with iloprost","year":"1992","journal-title":"Toxicol Lett"},{"key":"hep30197-bib-0060-20250401","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/jcpt.12094","article-title":"An evaluation of the pharmacokinetics of treprostinil diolamine in subjects with hepatic impairment","volume":"38","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"hep30197-bib-0061-20250401","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1586\/egh.12.83","article-title":"Assessing portal hypertension in liver diseases","volume":"7","year":"2013","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"hep30197-bib-0062-20250401","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jhep.2012.03.007","article-title":"Functional aspects on the pathophysiology of portal hypertension in cirrhosis","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"hep30197-bib-0063-20250401","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.rmed.2014.04.004","article-title":"Clinical aspects of portopulmonary hypertension","volume":"108","year":"2014","journal-title":"Respir Med"},{"key":"hep30197-bib-0064-20250401","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1053\/jhep.2002.31432","article-title":"The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough","volume":"35","year":"2002","journal-title":"Hepatology"},{"key":"hep30197-bib-0065-20250401","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.44.5.749","article-title":"Hepatic and splanchnic nitric oxide activity in patients with cirrhosis","volume":"44","year":"1999","journal-title":"Gut"},{"key":"hep30197-bib-0066-20250401","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1172\/JCI119842","article-title":"Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids","volume":"100","year":"1997","journal-title":"J Clin Invest"},{"key":"hep30197-bib-0067-20250401","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1042\/CS20090601","article-title":"Administration of a low dose of sildenafil for 1 week decreases intrahepatic resistance in rats with biliary cirrhosis: the role of NO bioavailability","volume":"119","year":"2010","journal-title":"Clin Sci (Lond)"},{"key":"hep30197-bib-0068-20250401","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/j.1872-034X.2008.00388.x","article-title":"Acute administration of sildenafil enhances hepatic cyclic guanosine monophosphate production and reduces hepatic sinusoid resistance in cirrhotic patients","volume":"38","year":"2008","journal-title":"Hepatol Res"},{"key":"hep30197-bib-0069-20250401","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2036.2006.02735.x","article-title":"Effect of vardenafil, an inhibitor of phosphodiesterase\u20105, on portal haemodynamics in normal and cirrhotic liver\u2014results of a pilot study","volume":"23","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"hep30197-bib-0070-20250401","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1111\/j.1572-0241.2002.05876.x","article-title":"Sildenafil (Viagra) is a risk factor for acute variceal bleeding","volume":"97","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"hep30197-bib-0071-20250401","doi-asserted-by":"crossref","first-page":"6208","DOI":"10.3748\/wjg.14.6208","article-title":"Sildenafil does not influence hepatic venous pressure gradient in patients with cirrhosis","volume":"14","year":"2008","journal-title":"World J Gastroenterol"},{"key":"hep30197-bib-0072-20250401","first-page":"P101","article-title":"The soluble guanylyl cyclase stimulator riociguat reduces liver fibrosis and portal pressure in cirrhotic rats","volume":"53","year":"2015","journal-title":"Z Gastroenterol"},{"issue":"Suppl. 3","key":"hep30197-bib-0073-20250401","first-page":"54","article-title":"Endothelin and endothelin receptor antagonism in portopulmonary hypertension","volume":"36","year":"2006","journal-title":"Eur J Clin Invest"},{"key":"hep30197-bib-0074-20250401","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1517\/13543780802680186","article-title":"Endothelin receptor antagonism in portal hypertension","volume":"18","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"hep30197-bib-0075-20250401","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/hep.510280308","article-title":"Beneficial hemodynamic effects of bosentan, a mixed ETA and ETB receptor antagonist, in portal hypertensive rats","volume":"28","year":"1998","journal-title":"Hepatology"},{"key":"hep30197-bib-0076-20250401","doi-asserted-by":"crossref","first-page":"G27","DOI":"10.1152\/ajpgi.90405.2008","article-title":"Endothelin antagonism in portal hypertensive mice: implications for endothelin receptor\u2010specific signaling in liver disease","volume":"297","year":"2009","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"hep30197-bib-0077-20250401","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/hep.1840180322","article-title":"Role of prostacyclin in hemodynamic alterations in conscious rats with extrahepatic or intrahepatic portal hypertension","volume":"18","year":"1993","journal-title":"Hepatology"},{"key":"hep30197-bib-0078-20250401","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0016-5085(86)91124-8","article-title":"Increased synthesis of systemic prostacyclin in cirrhotic patients","volume":"90","year":"1986","journal-title":"Gastroenterology"},{"key":"hep30197-bib-0079-20250401","doi-asserted-by":"crossref","first-page":"D34","DOI":"10.1016\/j.jacc.2013.10.029","article-title":"Updated clinical classification of pulmonary hypertension","volume":"62","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"hep30197-bib-0080-20250401","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"hep30197-bib-0081-20250401","doi-asserted-by":"crossref","first-page":"2522\u2010","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"hep30197-bib-0082-20250401","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"key":"hep30197-bib-0083-20250401","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/lt.21365","article-title":"Treatment of portopulmonary hypertension\u2014isn't it time to move forward?","volume":"14","year":"2008","journal-title":"Liver Transpl"},{"key":"hep30197-bib-0084-20250401","doi-asserted-by":"crossref","first-page":"D60","DOI":"10.1016\/j.jacc.2013.10.031","article-title":"Updated treatment algorithm of pulmonary arterial hypertension","volume":"62","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"hep30197-bib-0085-20250401","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.dld.2016.10.010","article-title":"Oral pulmonary vasoactive drugs achieve hemodynamic eligibility for liver transplantation in portopulmonary hypertension","volume":"49","year":"2017","journal-title":"Dig Liver Dis"},{"key":"hep30197-bib-0086-20250401","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/lt.21479","article-title":"Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation","volume":"15","year":"2009","journal-title":"Liver Transpl"},{"key":"hep30197-bib-0087-20250401","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1155\/2015\/810376","article-title":"Effectiveness of phosphodiesterase\u20105 inhibitor therapy for portopulmonary hypertension","volume":"22","year":"2015","journal-title":"Can Respir J"},{"key":"hep30197-bib-0088-20250401","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/lt.21533","article-title":"Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension","volume":"15","year":"2009","journal-title":"Liver Transpl"},{"key":"hep30197-bib-0089-20250401","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/hep.510300307","article-title":"Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension","volume":"30","year":"1999","journal-title":"Hepatology"},{"key":"hep30197-bib-0090-20250401","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00408-013-9501-5","article-title":"Early initiation of prostacyclin in portopulmonary hypertension: 10 years of a transplant center's experience","volume":"191","year":"2013","journal-title":"Lung"},{"key":"hep30197-bib-0091-20250401","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/00007890-199702270-00020","article-title":"Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension","volume":"63","year":"1997","journal-title":"Transplantation"},{"key":"hep30197-bib-0092-20250401","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1111\/j.1600-6143.2006.01432.x","article-title":"Successful liver transplantation following medical management of portopulmonary hypertension: a single\u2010center series","volume":"6","year":"2006","journal-title":"Am J Transplant"},{"key":"hep30197-bib-0093-20250401","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/lt.21174","article-title":"Long\u2010term follow\u2010up of portopulmonary hypertension: effect of treatment with epoprostenol","volume":"13","year":"2007","journal-title":"Liver Transpl"},{"key":"hep30197-bib-0094-20250401","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1097\/TP.0000000000001666","article-title":"Predictors of waitlist mortality in portopulmonary hypertension","volume":"101","year":"2017","journal-title":"Transplantation"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.30197","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201901000-00034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T09:44:11Z","timestamp":1743673451000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201901000-00034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,18]]},"references-count":94,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.30197","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,18]]},"assertion":[{"value":"2018-02-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}